Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% on an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong stock selection in pharmaceuticals, biotechnology, health care equipment, and life sciences tools and services supported the Fund’s outperformance, although limited exposure to managed care stocks reduced relative returns. The Fund remains positive on health care due to improving biotechnology funding, strong acquisition activity, recovering managed care margins, and growth from an aging population, chronic disease, medical innovation, and higher health care spending. In addition, please check the Fund’s top five holdings to know the best picks in 2026.
In its second-quarter 2026 investor letter, Baron Health Care Fund highlighted Guardant Health, Inc. (NASDAQ:GH). Guardant Health, Inc. (NASDAQ:GH) is a US based precision oncology company that provides blood and tissue tests, along with data sets. On August 04, 2026, Guardant Health, Inc. (NASDAQ:GH) closed at $159.79 per share. The one-month return of Guardant Health, Inc. (NASDAQ:GH) was 2.32% and its shares gained 258.35% over the past 52 weeks. Guardant Health, Inc. (NASDAQ:GH) has a market capitalization of $21.44 billion with a 52-week trading range between $40.36 – $176.58.
Baron Health Care Fund stated the following regarding Guardant Health, Inc. (NASDAQ:GH) in its Q2 2026 investor letter:
“Guardant Health, Inc. (NASDAQ:GH) is a specialty diagnostics company best known for its blood-based liquid biopsy tests used in cancer therapy selection, monitoring, and screening. Shares increased following strong first-quarter results, with revenue growing 48% year over-year due to continued adoption of the Guardant360 cancer treatment selection test and accelerating uptake of the Shield colorectal cancer blood test. Guardant360 continues to gain share within the rapidly growing liquid biopsy market, with momentum accelerating following FDA approval of the new Guardant360 Liquid CDx assay, which should qualify for Advanced Diagnostic Laboratory Test status and meaningfully expand average selling prices. Meanwhile, Shield has the potential to drive meaningful upside as adoption continues to beat expectations. Notably, the American Cancer Society recently recommended Shield in its updated colorectal cancer screening guidelines, significantly increasing the potential for expanded commercial insurance coverage. Looking ahead, we see Guardant360, Shield, and Reveal (Guardant’s cancer recurrence monitoring test) positioning the company to achieve positive free cash flow over time.”
Guardant Health, Inc. (NASDAQ:GH) is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 58 hedge fund portfolios held Guardant Health, Inc. (NASDAQ:GH) at the end of the first quarter which was 62 in the previous quarter. While we acknowledge the risk and potential of Guardant Health, Inc. (NASDAQ:GH) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Guardant Health, Inc. (NASDAQ:GH) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Guardant Health, Inc. (NASDAQ:GH) and shared Fred Alger Managements’ insight on the company. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
